| Business Summary | | La
Jolla
Pharmaceutical
Company
(LJPC)
is
a
biopharmaceutical
company
that
is
focused
on
the
research
and
development
of
highly
specific
therapeutics
for
the
treatment
of
certain
life-threatening
antibody-mediated
diseases.
These
diseases,
including
autoimmune
conditions
such
as
lupus
and
antibody-mediated
stroke,
are
caused
by
abnormal
B
cell
production
of
antibodies
that
attack
healthy
tissues.
The
Company's
drug
candidates,
called
Toleragens,
are
designed
to
treat
the
underlying
cause
of
many
antibody-mediated
diseases
without
the
severe,
adverse
side
effects
common
to
other
treatments.
The
Company
is
analyzing
data
from
a
Phase
III
clinical
trial
of
its
lupus
drug
candidate,
LJP
394,
and
its
clinical
drug
candidate
for
the
treatment
of
antibody-mediated
thrombosis,
known
as
LJP
1082,
is
currently
being
evaluated
in
toxicology
studies
that
are
required
prior
to
the
initiation
of
clinical
trials. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | La
Jolla
Pharmaceutical
is
a
biopharmaceutical
company
focused
on
the
research
and
development
of
highly
specific
therapeutics
for
the
treatment
of
certain
life
threatening
antibody-mediated
diseases.
For
the
six
months
ended
6/30/01,
Company
reported
no
revenues.
Net
loss
totalled
$12.7
million,
up
from
$5.9
million.
Results
reflect
the
absence
of
collaborative
payments
from
third
parties.
Higher
loss
reflects
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Steven Engle, 46 Chairman,
Pres, CEO | $403K | Matthew Linnik, Ph.D., 41 Exec.
VP- Research, Assistant Sec. | 234K | Paul Jenn, Ph.D., 50 VP-Operations | -- | William Welch, 37 VP
of Marketing | -- | Theodora Reilly, 51 VP
of HR | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|